Federico Alessandro, Zappavigna Silvia, Dallio Marcello, Misso Gabriella, Merlino Francesco, Loguercio Carmela, Novellino Ettore, Grieco Paolo, Caraglia Michele
Department of Clinical and Experimental Medicine, Second University of Naples, Via Pansini 5 80131 Naples, Italy. Select country.
Curr Cancer Drug Targets. 2017;17(2):109-121. doi: 10.2174/1568009616666160621101248.
Urotensin II and Urotensin-II receptors are important molecular factors that regulate vasoconstriction and all the diseases that are linked to abnormalities in blood pressure regulation (i.e.: hypertension, kidney diseases, cirrhosis etc.). Recently, Urotensin II and its receptor have also been involved in metabolic syndrome, diabetes and schizophrenia. Recent strong findings suggest that Urotensin II and its receptor are involved in the onset and development of different epithelial cancers. Indeed, it was reported that cell growth, motility and invasion in human breast, bladder, prostate, colorectal and glioblastoma cancer cells were regulated by Urotensin II and Urotensin-II receptor axis. This axis also regulated focal adhesion kinase and small Guanosine-5'-triphosphate binding proteins that likely had a role in motility and invasion mediated by Urotensin-II receptor. Additionally, its expression on tumour tissues is variably associated to the prediction of the clinical outcome of the patients and it can be considered an alternative molecular marker to be used as prognostic factor in human cancers. In conclusion, a new weapon in the treatment of human cancers is highlighting a new scenario for the future.
尾加压素 II 及其受体是调节血管收缩以及所有与血压调节异常相关疾病（如：高血压、肾脏疾病、肝硬化等）的重要分子因素。最近，尾加压素 II 及其受体还与代谢综合征、糖尿病和精神分裂症有关。近期有力的研究结果表明，尾加压素 II 及其受体参与了不同上皮癌的发生和发展。事实上，据报道，人乳腺癌、膀胱癌、前列腺癌、结直肠癌和胶质母细胞瘤细胞中的细胞生长、运动和侵袭受尾加压素 II 及其受体轴调控。该轴还调节粘着斑激酶和小 GTP 结合蛋白，它们可能在尾加压素 II 受体介导的运动和侵袭中发挥作用。此外，其在肿瘤组织上的表达与患者临床结局的预测存在不同程度的关联，并且可被视为一种用于人类癌症预后因素的替代分子标志物。总之，治疗人类癌症的一种新武器正在为未来勾勒出一个新的局面。
